Simultaneous interfacility transfer of multiple non-critically ill COVID-19 patients using a single vehicle: the ambulance bus experience.

BACKGROUND: During the COVID-19 pandemic, hospital capacity in the Netherlands has been pushed to its limits. In order to prevent hospitals from collapse due to capacity issues, hospitalized COVID-19 patients were redistributed throughout the country. The numerous individual interfacility transfers further increased the pressure on emergency medical services (EMS), which simultaneously had to serve the community during the pandemic. In this report, we evaluate the interfacility transport of multiple non-critically ill COVID-19 patients using one single vehicle: a coach converted into an ambulance bus. DISCUSSION: Between March 28, 2020, and July 17, 2021, the ambulance bus was dispatched 22 times. In total, 102 patients were transferred over a mean distance of 79.6 km. No technical or patient-related adverse events were reported. The primary benefits of the ambulance bus were its time and staff reducing potential, as well as the ability to provide relief to overwhelmed hospitals. Furthermore, it could be assembled from existing equipment in a relatively short time span. However, the efficiency of dispatches and matching between hospitals could be improved. CONCLUSION: The simultaneous interfacility transfer of multiple non-critically ill COVID-19 patients using an ambulance bus was feasible. No technical or patient-related adverse events were reported during 22 dispatches, involving a total of 102 patients. This mode of transport may also be useful in non-pandemic situations, such as hospital and nursing home evacuations.

Temporal patterns and short-term progression of paroxysmal atrial fibrillation: data from RACE V.

AIMS: Atrial fibrillation (AF) often starts as a paroxysmal self-terminating arrhythmia. Limited information is available on AF patterns and episode duration of paroxysmal AF. In paroxysmal AF patients, we longitudinally studied the temporal AF patterns, the association with clinical characteristics, and prevalence of AF progression. METHODS AND RESULTS: In this interim analysis of the Reappraisal of AF: Interaction Between HyperCoagulability, Electrical Remodelling, and Vascular Destabilisation in the Progression of AF (RACE V) registry, 202 patients with paroxysmal AF were followed with continuous rhythm monitoring (implantable loop recorder or pacemaker) for 6 months. Mean age was 64 ± 9 years, 42% were women. Atrial fibrillation history was 2.1 (0.5-4.4) years, CHA2DS2-VASc 1.9 ± 1.3, 101 (50%) had hypertension, 69 (34%) heart failure. One-third had no AF during follow-up. Patients with long episodes (>12 hours) were often men with more comorbidities (heart failure, coronary artery disease, higher left ventricular mass). Patients with higher AF burden (>2.5%) were older with more comorbidities (worse renal function, higher calcium score, thicker intima media thickness). In 179 (89%) patients, 1-year rhythm follow-up was available. On a quarterly basis, average daily AF burden increased from 3.2% to 3.8%, 5.2%, and 6.1%. Compared to the first 6 months, 111 (62%) patients remained stable during the second 6 months, 39 (22%) showed progression to longer AF episodes, 8 (3%) developed persistent AF, and 29 (16%) patients showed AF regression. CONCLUSIONS: In paroxysmal AF, temporal patterns differ suggesting that paroxysmal AF is not one entity. Atrial fibrillation burden is low and determined by number of comorbidities. Atrial fibrillation progression occurred in a substantial number. TRIAL REGISTRATION NUMBER: Clinicaltrials.gov identifier NCT02726698.

Correlating both Aldrich and Hellemond score with cardiac magnetic resonance imaging endocardial surface area calculations in the estimation of the area at risk. Electrocardiography scores and endocardial surface area calculations: do they correlate?

INTRODUCTION: Having a bedside tool such as the ECG to assess the myocardial area at risk in a patient presenting with an ST-elevation myocardial infarction would be of great value to the clinician because this could give an insight in the efficiency of intervention therapy and the left ventricular rest function. MATERIALS AND METHODS: From the MAST database (n=106), we included 84 patients, all meeting the STEMI criteria, with a first anterior and/or inferior STEMI. From the admission ECG the Aldrich and Selvester scores were measured and the combined Hellemond score was calculated and correlated with the Cardiac Magnetic Resonance (CMR) estimated endocardial surface area (ESA) using the Spearman coefficient. RESULTS: The correlation between the Aldrich score was r=0.55 (p-value<0.0001) and Hellemond score r=0.45 (p-value<0.0001) with ESA. After exclusion of lateral involvement the correlation increased to 0.62 (p-value<0.0001) for the Aldrich and to 0.49 (p-value<0.0001) for the Hellemond score. CONCLUSION: The additional ECG estimation of infarcted myocardium does not improve the ECG estimation of ischemic myocardium to CMR-based ESA estimation of the myocardial area at risk. The Aldrich score could be improved for STEMIs with lateral involvement.